Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_assertion type Assertion NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_head.
- NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_assertion description "[This research highlights new bioactivities for gracilins, such as BACE1 and ERK inhibition, and provides more evidence for their potential therapeutic application in neurodegenerative diseases due to their multi-target activities, especially in AD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_provenance.
- NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_assertion evidence source_evidence_literature NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_provenance.
- NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_assertion SIO_000772 25724081 NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_provenance.
- NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_assertion wasDerivedFrom befree-2016 NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_provenance.
- NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_assertion wasGeneratedBy ECO_0000203 NP1266819.RAwEo9T5ErEudqLhs3IDNDpkd-fiP6Fu0jt5zJFxahTAY130_provenance.